Hepatocellular carcinoma: PIVKA-II may be unsuitable for Indian patients
With its higher false positivity rate, PIVKA-II may not be a reliable marker for HCC, although it may be useful in larger HCC lesions and in AFP-negative patients. Establishing a newer cutoff value for PIVKA-II among the Indian population may improve its specificity in the diagnosis and management of HCC.
Authors
- Ambili Kariaparambil Rajan
- Sathish Srinivasan (ORCID: https://orcid.org/0000-0001-9678-9971)
- Komalavalli Subbiah
- Hemalatha Ramachandran
- Evangeline Simon
- Lexmi Priya Raju
- Mukul Vij (ORCID: https://orcid.org/0000-0003-0149-0294)
- Dinesh Kumar Jothimani (ORCID: https://orcid.org/0000-0003-4189-690X)
- Mohamed Rela
Institutions
- Tamil Nadu Dr. M.G.R. Medical University (IN)
Publication Details
- Journal
- Laboratory Medicine
- Published
- 2025-09-09
- DOI
- https://doi.org/10.1093/labmed/lmaf065
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00